TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8877678
Drug: One transdermal
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: One transdermal delivery system
Study: 8877678
Drug: Two transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two transdermal delivery systems
Study: 8877678
Drug: Three transdermal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three transdermal delivery systems
Study: 8877678
Drug: Two to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two to three transdermal delivery systems
Study: 8877678
Drug: Standard recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard recommended dose of two transdermal delivery systems
Study: 1643987
Drug: Breast preservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast preservation therapy
Study: 27635789
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (120 kVp, 45 mAs)
Study: 27554662
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT (120 kVp, 100 mAs)
Study: 22927772
Drug: Pharmacogenetic-based warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic-based warfarin dosing algorithm (based on CYP2C9 and VKORC1 genotypes)
Study: 18076560
Drug: Any anaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any anaemia (haemoglobin < 11 g/dl)
Study: 18076560
Drug: Moderate anaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate anaemia (haemoglobin < 8 g/dl)
Study: 8103876
Drug: Glucose-based ORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based ORS solution
Study: 3713254
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg Mg/day (as magnesium citrate tablets)
Study: 27494036
Drug: Sequential arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential arm (SA): induction cisplatin-5fluorouracil followed by 70Gy-RT for responders or total laryngectomy and post-operative RT for non-responders
Study: 27494036
Drug: Alternating arm
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating arm (AA): cisplatin-5fluorouracil alternated with three 2-week courses of 20Gy-RT for a total dose of 60Gy
Study: 23069788
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects repeated the surgical procedure twice
Study: 18765484
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day of aripiprazole
Study: 18765484
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of aripiprazole
Study: 31075675
Drug: In-vivo One-Session
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-vivo One-Session Treatment (OST)
Study: 29606861
Drug: FF MDI
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF MDI 10 μg
Study: 22790008
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine (bolus at induction, continuous infusion during surgery and first 48 hours postoperatively)
Study: 22790008
Drug: i.v. placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. placebo (saline solution under the same infusion modalities)
Study: 12040967
Drug: Pitavastatin 1
Normalized name: PITAVASTATIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 1 mg/day or more
Study: 12040967
Drug: Pitavastatin 1
Normalized name: PITAVASTATIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 1 mg/day to 4 mg/day
Study: 12799977
Drug: Low-energy shock-wave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy shock-wave therapy (3000 impulses of 0.08 mJ/mm(2))
Study: 1699337
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for pulmonary tuberculosis
Study: 6451422
Drug: beta 2-Sympathomimetic
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta 2-Sympathomimetic drugs
Study: 31040642
Drug: Choline alfoscerate
Normalized name: Choline Alfoscerate
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline alfoscerate tablet (1,200 mg, 400 mg × three doses)
Study: 31040642
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule (Gliatilin®) (1,200 mg, 400 mg × three doses)
Study: 31040642
Drug: Choline alfoscerate
Normalized name: Choline Alfoscerate
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline alfoscerate tablet vs Soft gelatin capsule
Study: 25074771
Drug: Lutein 20
Normalized name: lutein 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein 20 mg/d
Study: 25074771
Drug: Lutein 20
Normalized name: lutein 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein 20 mg/d (in patients with low plasma lutein)
Study: 23182475
Drug: Deslorelin acetate
Normalized name: Deslorelin Acetate
DrugBank: Deslorelin (DB11510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deslorelin acetate (100 μg IM every 12h)
Study: 12560148
Drug: Preparation book
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation book for surgery (experimental group)
Study: 12560148
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation book (control group)
Study: 10221357
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg propranolol hydrochloride
Study: 27347553
Drug: Clinpro Tooth
Normalized name: sodium fluoride 0.950 mg in 1 g ORAL PASTE, DENTIFRICE [Clinpro Tooth Creme]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinpro Tooth Crème (brushing + additional topical application)
Study: 22930148
Drug: Low-dose magnesium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose magnesium sulphate (9 g loading dose: 4 g iv and 5 g im; maintenance 2.5 g im every 4 hours for 24 hours)
Study: 22930148
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose magnesium sulphate (14 g loading dose; maintenance 5 g im every 4 hours)
Study: 12917302
Drug: Cyclosporine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (3 mg per kilogram of body weight per day)
Study: 31034251
Drug: PS-W (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS-W (daily consumption of margarine containing 2 g/day of plant sterols with 30-min daily walking)
Study: 31034251
Drug: C-S (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-S (daily consumption of control margarine while sedentary)
Study: 31034251
Drug: PS-S (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS-S (daily consumption of margarine containing 2 g/day of plant sterols while sedentary)
Study: 31034251
Drug: C-W (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-W (daily consumption of control margarine with 30-min daily walking)
Study: 28544241
Drug: RRR-α-tocopherol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-α-tocopherol supplementation (400 IU single dose)
Study: 23937010
Drug: Myrtol Standardized
Normalized name: myrtol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrtol Standardized Enteric Coated Soft Capsules, 0.3 g, 3 times a day, for 3 months
Study: 23937010
Drug: Myrtol Standardized
Normalized name: myrtol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrtol Standardized Enteric Coated Soft Capsules
Study: 17031646
Drug: CP‐547,632 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐547,632 plus paclitaxel (225 mg/m²) and carboplatin (AUC = 6) every 3 weeks
Study: 17031646
Drug: CP‐547,632 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐547,632 plus chemotherapy
Study: 14615471
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 (50 mg, 100 mg, 200 mg twice daily and 200 mg thrice daily)
Study: 10754780
Drug: E2 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 supplementation (2 mg two times daily) from the early proliferative phase to the late secretory phase of the endometrium
Study: 10754780
Drug: E2 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 supplementation (2 mg two times daily)
Study: 3872835
Drug: Nicardipine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (7.5 mg)
Study: 3872835
Drug: Verapamil (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (16 mg)
Study: 28961380
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (magnetic stimulation)
Study: 26100611
Drug: HORIZON trauma
Normalized name: Horizant
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HORIZON trauma focused cognitive behavioral therapy with parental components
Study: 15136099
Drug: Endometrial sampling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial sampling and measurement of serum estradiol and progesterone 1 to 14 days after the midcycle urinary luteinizing hormone surge.
Study: 11841079
Drug: Gastrografin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin 200 ml orally for 2 consecutive days before operation
Study: 11841079
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution through a nasogastric tube
Study: 10463377
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg physostigmine patch
Study: 10463377
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg physostigmine patch
Study: 7595767
Drug: Neonatal amino
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal amino acid formulation
Study: 7595767
Drug: General-purpose intravenous
Normalized name: Corona Multi-Purpose
Approvals — FDA: no, EMA: no, PMDA: no
Description: General-purpose intravenous amino acid solution
Study: 28202013
Drug: Clarithromycin-based sequential
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin-based sequential treatment (10-day regimen: Proton-Pump Inhibitor + Amoxicillin 1 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronidazole/Tinidazole 500 mg bid/tid for the following 5 days)
Study: 28202013
Drug: Levofloxacin-based sequential
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based sequential treatment (10-day modified regimen with Levofloxacin 500 mg id instead of Clarithromycin)
Study: 22799528
Drug: Extraction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction treatment (Group 1)
Study: 22799528
Drug: Nonextraction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextraction treatment (Group 2)
Study: 21492764
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg daily (without LDL-C <50 mg/dl)
Study: 8889317
Drug: Propranolol (PRO)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (PRO) 80 mg x 2/day for 7 days
Study: 8889317
Drug: Pindolol (PIN)
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol (PIN) 10 mg x 2/day for 7 days
Study: 1824585
Drug: Ephedrine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (0.5 mg/kg)
Study: 1824585
Drug: Droperidol (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.04 mg/kg)
Study: 6407438
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 or 360 mg/day
Study: 2883817
Drug: temazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: temazepam (20 mg/day)
Study: 2883817
Drug: flunitrazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunitrazepam (2 mg/day)
Study: 29084042
Drug: Local drug
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local drug delivery of abciximab (IL, by the ClearWay catheter) plus aspiration thrombectomy (AT)
Study: 29084042
Drug: Nonlocal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonlocal drug delivery of abciximab (IC, by the guide catheter) plus aspiration thrombectomy (AT)
Study: 26971071
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy for psychosis based Guided Self-help (CBTp-GSH)
Study: 23906195
Drug: Age, use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, use of antiarrhythmic drugs, and AEMI
Study: 22252094
Drug: pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill placebo (PLA‐CM)
Study: 18322988
Drug: Somatic absorption
Normalized name: Bos taurus somatic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatic absorption
Study: 16124422
Drug: 4 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg/day of artesunate for 3 days and 3 daily doses of 8.0 mg/kg/day mefloquine
Study: 16124422
Drug: 4 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg/day of artesunate for 3 days and mefloquine given as 15 mg/kg on the first day and 10 mg/kg on the second day
Study: 6342784
Drug: Fenbufen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen (600 mg daily)
Study: 30255637
Drug: Play activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Play activities program (1 hour weekly for 8 weeks)
Study: 30255637
Drug: Reading books
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading books and magazines (15 minutes weekly for 8 weeks)
Study: 24878457
Drug: Interval appendectomy
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval appendectomy (4-6 weeks after initial treatment with antibiotics)
Study: 18321181
Drug: Overall study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall study population (n = 35 who initiated treatment)
Study: 15557136
Drug: 500 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ppm CO inhalation for 1 hour
Study: 15557136
Drug: Synthetic air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic air (placebo) inhalation
Study: 12218381
Drug: High-dose estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose estrogen plus methyltestosterone
Study: 12218381
Drug: High-dose estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose estrogen
Study: 10671963
Drug: 5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl peroxide cream
Study: 8874253
Drug: 2 days
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of i.v. antibiotics followed by 8 days of oral therapy
Study: 8874253
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of i.v. antibiotics followed by 5 days of oral therapy
Study: 8874253
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of i.v. antibiotics
Study: 1686784
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 mg once a day, at 0700 h)
Study: 29882087
Drug: Riociguat 0.5
Normalized name: riociguat 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat 0.5 mg
Study: 29882087
Drug: Riociguat 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat 1.0 mg
Study: 29882087
Drug: Biperiden 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 2.0 mg
Study: 29882087
Drug: Biperiden 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 2.0 mg and Riociguat 0.5 mg
Study: 29882087
Drug: Biperiden 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 2.0 mg and Riociguat 1.0 mg
Study: 29798272
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (radiotherapy)
Study: 23075703
Drug: lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir (LPV/r) 400/100 mg twice daily monotherapy (mono‐LPV/r)
Study: 23075703
Drug: tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r)
Study: 20574412
Drug: Quadrivalent human
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent human papillomavirus vaccine (QHPV)
Study: 18664696
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (CBT) package for social anxiety
Study: 18664696
Drug: Speech restructuring
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech restructuring treatment alone
Study: 17057794
Drug: Mitomycin 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin 0.25 mg/mL for 1 minute combined with temporary nasal tarsorrhaphy
Study: 12271112
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) self-help manual in six modules
Study: 7792546
Drug: Multimodal cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cognitive-behavioural treatments (MMCBT) with psychologist as a coach (Group A)
Study: 7792546
Drug: Multimodal cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cognitive-behavioural treatments (MMCBT) with direct psychologist contact (Group B)
Study: 1706610
Drug: T-cell ML
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell ML
Study: 1706610
Drug: B-cell ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-cell ML
Study: 19090439
Drug: Surgery, adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, adjuvant treatment, or radiotherapy
Study: 14654574
Drug: Angiotensin-II antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-II antagonists
Study: 9168214
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine (10 mg in 20 mL normal saline)
Study: 9168214
Drug: Intra-articular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular bupivacaine (20 mL 0.5% with epinephrine)
Study: 9168214
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (10 mg in 1 mL)
Study: 9168214
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL IA normal saline + 1 mL SC normal saline)
Study: 8063651
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg/day; n = 6)
Study: 2646850
Drug: Propofol (1.5-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5-2.0 mg/kg i.v. combined with diazepam 0.2 mg/kg i.v.)
Study: 2646850
Drug: Thiopentone (3.0-4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (3.0-4.0 mg/kg i.v. combined with diazepam 0.2 mg/kg i.v.)
Study: 21273301
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment for Women with Alcohol Addiction (EWA)
Study: 20387350
Drug: Pethidine (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (0.35 mg/kg)
Study: 20387350
Drug: Doxapram (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (1.5 mg/kg)
Study: 11529248
Drug: phVEGF165 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: phVEGF165 gene transfer (1, 2, or 4 mg)
Study: 7620002
Drug: Ceftazidime monotherapy
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime monotherapy
Study: 24974155
Drug: Prednisone 50
Normalized name: prednisone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 50 mg for 7 days
Study: 25628082
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - Edgewise therapy only
Study: 17766699
Drug: Rituximab alone
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab alone (1000 mg administered intravenously on days 1 and 15)
Study: 17766699
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus cyclophosphamide (750 mg administered intravenously on days 3 and 17)
Study: 17766699
Drug: Methotrexate alone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate alone (10-25 mg/wk)
Study: 15077929
Drug: CYFRA 21-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYFRA 21-1 in F0 expressed in ng/mg TP
Study: 15077929
Drug: NSE in
Normalized name: Good Sense Infants Pain Reliver
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSE in both fractions expressed in ng/mg TP
Study: 15077929
Drug: SCC in
Normalized name: SCC
DrugBank: Sodium copper chlorophyllin (DB16522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCC in F1 expressed in ng/mg TP
Study: 15077929
Drug: TPA in
Normalized name: zinc-DTPA Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA in F0 expressed in mU/mg TP
Study: 15077929
Drug: TPS in
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TPS in both fractions expressed in mU/mg TP
Study: 11229833
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral vitamin K1
Study: 11229833
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of one dose of acenocoumarine
Study: 2091170
Drug: Concurrent visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent visual feedback during abduction of the fifth digit